How giant cell arteritis affects eyesight, studied with detailed eye imaging
Compares eye findings in giant cell arteritis and other causes of vision loss.
Key facts
- Who runs it
- ASST Fatebenefratelli Sacco
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Visual Involvement in Giant Cell Arteritis
- Status
- Recruiting
- People taking part
- 762 people, planned
- Started
- 27 Jun 2024
- Expected to end
- Jun 2030
- Type of study
- Observational, 2 groups
- Treatments tested
- Fluorescein and Indocyanine green Angiography
- High-resolution Optical Coherence Tomography
- Angio-Optical Coherence Tomography
- Record updated
- 15 July 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with new vision problems. One group has giant cell arteritis (GCA), an inflammation of blood vessels. The other group has similar eye damage from other causes.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Newly found sudden vision loss. In the GCA group, GCA is suspected or confirmed and the vision loss is thought to be linked to it. In the control group, the eye damage looks like GCA (for example AION, CRAO) but is not caused by vessel inflammation.
Main reasons for not taking part
- Eye diseases from before that may change sight or the eye exam findings.
- Active infections (viral, bacterial, fungal, parasitic), including tuberculosis treated for less than 4 weeks, and HIV, HCV or HBV infections involving the eyes and eye sockets.
- Other body-wide inflammation not caused by GCA (diseases in remission without treatment are allowed).
- Any other condition the study doctors judge rules out taking part.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- For GCA group:; Patients older than 18 years with clinically suspected or confirmed gigantocellular arteritis; Newly found visual involvement with suspected or confirmed correlation with vasculitis; Ability to express valid consent to study enrolment
- For control group:; Patients older than 18 years with the ability to express valid consent to study enrolment; Newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology
Who cannot take part
- Concomitant active viral, bacterial, fungal and parasitic infections, including active or latent tuberculosis treated for less than 4 weeks and HIV, hepatitis C virus (HCV); /hepatitis B virus (HBV) infections, involving the eyes and orbital cavities
- Concomitant systemic inflammations not attributable to GCA (inflammatory diseases in treatment-free remission are not excluded)
- Any other condition judged by the investigators to be a contraindication of eligibility
- Pre-existing ophthalmological pathologies that may modify best visual acuity and/or alter ophthalmological semeiotics
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This observational study aims to enhance the description of the different ways Giant Cell Arteritis (GCA) affects vision. The latest technology and knowledge are used to improve how we diagnose and predict patient outcomes. GCA is the most frequent vasculitis, an inflammation of vessels, in older adults. It involves large and medium-sized arteries and causes ischemic alterations such as stroke and blindness, through damage of extracranial arteries.
Read full original descriptionShow less
The primary objective is to compare the frequency of the various ocular findings between the main alterations of arteritic and non-arteritic aetiology, such as Arteritic Anterior Ischemic Optic Neuropathy (A-AION) Vs. Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION) or Central Retinal Artery Occlusion (CRAO) from GCA Vs. from other causes, through a comprehensive clinical and instrumental evaluation.
The 2 groups in the trial
- GCA patients
Patients older than 18 years with clinically suspected or confirmed giant cell arteritis, who experience newly diagnosed visual impairment with suspected or confirmed correlation with vasculitis.
Treatment: Fluorescein and Indocyanine green Angiography, High-resolution Optical Coherence Tomography, and Angio-Optical Coherence Tomography
- Non arteritis patients
Patients over 18 years of age who experience newly diagnosed acute visual impairment with GCA phenotypes (e.g. AION, CRAO) but without any correlation with vasculitis aetiology.
Treatment: Fluorescein and Indocyanine green Angiography, High-resolution Optical Coherence Tomography, and Angio-Optical Coherence Tomography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Visual Involvement in Giant Cell Arteritis
- Plain-language title
- How giant cell arteritis affects eyesight, studied with detailed eye imagingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 15 July 2024